Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, VEEV has had strong sales and earnings growth: Also, EPS is estimated to ramp higher ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid fourth-quarter fiscal 2025 performance and strategic ...

Veeva (VEEV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

We came across a bullish thesis on Veeva Systems Inc. (VEEV) on Substack by Francesco Ferrari. In this article, we will ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the ...

Needham & Company LLC restated their buy rating on shares of Veeva Systems (NYSE:VEEV – Free Report) in a report released on ...

Stephens reissued their overweight rating on shares of Veeva Systems (NYSE:VEEV – Free Report) in a research note released on ...

Value investors believe that owning a stock is owning a slice of the underlying business… but this isn’t always true. Innovative corporate forms such as Special Purpose Vehicles (SPV) and (Variable ...

Veeva released Q4 result on March 5 th, reporting 14.3% revenue growth and 28.7% adj. operating profit growth, as detailed in ...

Veeva Systems (VEEV) is climbing 7% after delivering stronger-than-expected fourth-quarter results and providing full-year ...

Veeva Systems VEEV has outperformed the market over the past 10 years by 14.63% on an annualized basis producing an average ...